Zasocitinib: NextGen Allosteric TYK2 Inhibitor—Is the Hype Justified?
Commentary on Mehrotra S,………, McInnes IB, Pharmacological Characterization of Zasocitinib (TAK-279): An Oral, Highly Selective and Potent Allosteric TYK2 Inhibitor, The Journal of Investigative Dermatology (2025), doi: https://doi.org/10.1016/j.jid.2025.05.014.
a) Rationale, Objectives, and Novelty
The rationale for the Mehrotra et al. study stems from th…
Keep reading with a 7-day free trial
Subscribe to Drug Development Executive to keep reading this post and get 7 days of free access to the full post archives.